
GLUE Stock Forecast & Price Target
GLUE Analyst Ratings
Bulls say
Monte Rosa Therapeutics Inc has demonstrated a substantial increase in enterprise value, moving from $2.22 billion to $3.28 billion, underscoring the potential within its pipeline of molecular glue degraders (MGDs) and reflecting investor confidence. Notably, the valuation for the NEK7 MGD MRT-8102 has surged to $1.16 billion based on promising interim Phase I GFORCE-1 data, highlighting the therapeutic promise of this candidate. Additionally, projected year-end 2026 cash has risen significantly to $505 million, indicating a stronger financial position that supports the company's ability to advance its innovative MGD programs.
Bears say
Monte Rosa Therapeutics Inc faces a challenging landscape characterized by potential setbacks that could negatively impact its financial outlook. The company's partnership prospects with major players like Roche and Novartis appear uncertain, evidenced by recent setbacks in regulatory approvals and increased risks of competition. Additionally, inherent risks in research and development, intellectual property, and management execution further contribute to concerns over Monte Rosa's ability to successfully navigate market challenges and secure future collaborations.
This aggregate rating is based on analysts' research of Monte Rosa Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
GLUE Analyst Forecast & Price Prediction
Start investing in GLUE
Order type
Buy in
Order amount
Est. shares
0 shares